GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » PE Ratio (TTM)
中文

Integra Lifesciences Holdings (Integra Lifesciences Holdings) PE Ratio (TTM) : 35.40 (As of Apr. 25, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-25), Integra Lifesciences Holdings's share price is $29.38. Integra Lifesciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.83. Therefore, Integra Lifesciences Holdings's PE Ratio (TTM) for today is 35.40.


The historical rank and industry rank for Integra Lifesciences Holdings's PE Ratio (TTM) or its related term are showing as below:

IART' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 18.67   Med: 50.18   Max: 6776
Current: 35.4


During the past 13 years, the highest PE Ratio (TTM) of Integra Lifesciences Holdings was 6776.00. The lowest was 18.67. And the median was 50.18.


IART's PE Ratio (TTM) is ranked worse than
64.86% of 407 companies
in the Medical Devices & Instruments industry
Industry Median: 27.17 vs IART: 35.40

Integra Lifesciences Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.25. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.83.

As of today (2024-04-25), Integra Lifesciences Holdings's share price is $29.38. Integra Lifesciences Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $2.65. Therefore, Integra Lifesciences Holdings's PE Ratio without NRI for today is 11.09.

During the past 13 years, Integra Lifesciences Holdings's highest PE Ratio without NRI was 134.12. The lowest was 10.82. And the median was 37.94.

Integra Lifesciences Holdings's EPS without NRI for the three months ended in Dec. 2023 was $0.89. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $2.65.

During the past 12 months, Integra Lifesciences Holdings's average EPS without NRI Growth Rate was -61.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was -18.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 19.00% per year.

During the past 13 years, Integra Lifesciences Holdings's highest 3-Year average EPS without NRI Growth Rate was 93.10% per year. The lowest was -48.20% per year. And the median was 7.90% per year.

Integra Lifesciences Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $0.25. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.84.


Integra Lifesciences Holdings PE Ratio (TTM) Historical Data

The historical data trend for Integra Lifesciences Holdings's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings PE Ratio (TTM) Chart

Integra Lifesciences Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.48 41.35 33.83 25.96 51.85

Integra Lifesciences Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.96 27.87 26.20 31.56 51.85

Competitive Comparison of Integra Lifesciences Holdings's PE Ratio (TTM)

For the Medical Devices subindustry, Integra Lifesciences Holdings's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings's PE Ratio (TTM) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's PE Ratio (TTM) falls into.



Integra Lifesciences Holdings PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Integra Lifesciences Holdings's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=29.38/0.830
=35.40

Integra Lifesciences Holdings's Share Price of today is $29.38.
Integra Lifesciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.83.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Integra Lifesciences Holdings  (NAS:IART) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Integra Lifesciences Holdings PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Executives
Chantal Veillon-berteloot officer: EVP & CHRO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook officer: SVP, Fin & PAO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight officer: EVP & CFO 1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz officer: Corp VP, Gen Counsel & Sec C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De director, officer: President & CEO C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen officer: Executive VP & President, CSS 1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh officer: Exec VP & PRES, International 1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli officer: Chief Human Resources Officer 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy director 14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman officer: CVP, CHIEF FINANCIAL OFFICER C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p. 10 percent owner 795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini officer: President & COO 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay director 1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig director, officer: President and CEO 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Headlines

From GuruFocus

INTEGRA SHAREHOLDER ALERT

By PRNewswire 11-03-2023